CANDESARTAN CILEXETIL - SAFETY AND TOLERABILITY IN HEALTHY-VOLUNTEERSAND PATIENTS WITH HYPERTENSION

The tolerability and safety of candesartan cilexetil has been evaluate d in over 5000 subjects enrolled into double-blind or open-label clini cal studies. In double-blind clinical trials in patients with primary hypertension, candesartan cilexetil 2-16 mg once-daily was associated with a low incidence of adverse events and drug-related withdrawals, s imilar to placebo. The drug showed no evidence of dose-dependent adver se events and it was equally well tolerated by men and women and by el derly (greater than or equal to 65 years) and younger (<65 years) pati ents alike. Candesartan cilexetil had no effect on blood glucose contr ol or serum lipid profile in patients with type II diabetes. It was ve ry well tolerated also when given in combination with hydrochlorothiaz ide or amlodipine and during long-term open-label therapy (up to 1 yea r). Candesartan cilexetil therefore possesses an excellent tolerabilit y profile that extends to a wide variety of patients including the eld erly and it does not aggravate co-existing risk factors such as hyperl ipidaemia or glucose intolerance. It therefore appears to offer a bett er tolerated alternative to other commonly used antihypertensive agent s.